Multiple Myeloma (MM) Recruiting Phase 2 Trials for Fludarabine (DB01073)
Also known as: MULTIPLE MYELOMA (MM) / Multiple myeloma / Myeloma, Multiple / Multiple Myelomas / Multiple Myeloma(MM) / Plasma cell myelomas / Myelomatosis multiple / Peripheral plasma cell myeloma / Myelomatosis / Multiple myeloma myelomatosis / Plasma cell myeloma / Myeloma / Multiple myeloma with failed remission
Indication | Status | Phase |
---|---|---|
DBCOND0040908 (Multiple Myeloma (MM)) | Recruiting | 2 |
clinicaltrials.gov Identifier | Title | Purpose | Drugs |
---|---|---|---|
NCT01119066 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | Treatment | |
NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | Treatment | |
NCT02722668 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Treatment | |
NCT03159702 | Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation | Treatment | |
NCT02861417 | Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation | Treatment |